RESUMEN
Soft tissue sarcomas are rare malignant tumors derived from mesenchymal cells that have a high morbidity and mortality related to frequent occurrence of advanced and metastatic disease. Over the past two decades there have been significant advances in the use of targeted therapies for the treatment of soft tissue sarcoma. The ability to study various cellular markers and pathways related to sarcomagenesis has led to the creation and approval of multiple novel therapies. Herein, we describe the current landscape of targeted medications used in the management of advanced or metastatic soft tissue sarcomas, excluding GIST. We distinguish three categories: targeted therapies that have current US Food and Drug Administration (FDA) approval for treatment of soft tissue sarcoma, non-FDA approved targeted therapies, and medications in development for treatment of patients with soft tissue sarcoma.
RESUMEN
Synovial sarcoma is a soft tissue sarcoma accounting for approximately 1,000 cases per year in the United States. Currently, standard treatment of advanced and metastatic synovial sarcoma is anthracycline-based chemotherapy. While advanced synovial sarcoma is more responsive to chemotherapy compared to other soft tissue sarcomas, survival rates are poor, with a median survival time of less than 18 months. Enhanced understanding of tumor antigen expression and molecular mechanisms behind synovial sarcoma provide potential targets for treatment. Adoptive Cell Transfer using engineered T-cell receptors is in clinical trials for treatment of synovial sarcoma, specifically targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1), preferentially expressed antigen in melanoma (PRAME), and melanoma antigen-A4 (MAGE-A4). In this review, we explore the opportunities and challenges of these treatments. We also describe artificial adjuvant vector cells (aAVCs) and BRD9 inhibitors, two additional potential targets for treatment of advanced synovial sarcoma. This review demonstrates the progress that has been made in treatment of synovial sarcoma and highlights the future study and qualification needed to implement these technologies as standard of care.
RESUMEN
One obstacle for human solid tumor immunotherapy research is the lack of clinically relevant animal models. In this study, we sought to establish a chimeric antigen receptor (CAR) T-cell treatment model for naturally occurring canine sarcomas as a model for human CAR T-cell therapy. Canine CARs specific for B7-H3 were constructed using a single-chain variable fragment derived from the human B7-H3-specific antibody MGA271, which we confirmed to be cross-reactive with canine B7-H3. After refining activation, transduction, and expansion methods, we confirmed target killing in a tumor spheroid three-dimensional assay. We designed a B7-H3 canine CAR T-cell and achieved consistently high levels of transduction efficacy, expansion, and in vitro tumor killing. Safety of the CAR T cells were confirmed in two purposely bred healthy canine subjects following lymphodepletion by cyclophosphamide and fludarabine. Immune response, clinical parameters, and manifestation were closely monitored after treatments and were shown to resemble that of humans. No severe adverse events were observed. In summary, we demonstrated that similar to human cancers, B7-H3 can serve as a target for canine solid tumors. We successfully generated highly functional canine B7-H3-specific CAR T-cell products using a production protocol that closely models human CAR T-cell production procedure. The treatment regimen that we designed was confirmed to be safe in vivo. Our research provides a promising direction to establish in vitro and in vivo models for immunotherapy for canine and human solid tumor treatment.
Asunto(s)
Receptores Quiméricos de Antígenos , Sarcoma , Animales , Antígenos B7 , Línea Celular Tumoral , Perros , Humanos , Sarcoma/tratamiento farmacológico , Linfocitos T , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, little is known about the immune microenvironment in relation to patient prognosis. METHODS: We performed a retrospective study of 61 patients with DDLPS. We completed deep sequencing of the T-cell receptor (TCR) ß-chain and RNA sequencing for predictive modeling, evaluating both immune markers and tumor escape genes. Hierarchical clustering and recursive partitioning were employed to elucidate relationships of cellular infiltrates within the tumor microenvironment, while an immune score for single markers was created as a predictive tool. RESULTS: Although many DDLPS samples had low TCR clonality, high TCR clonality combined with low T-cell fraction predicted lower 3-year overall survival (p=0.05). Higher levels of CD14+ monocytes (p=0.02) inversely correlated with 3-year recurrence-free survival (RFS), while CD4+ T-cell infiltration (p=0.05) was associated with a higher RFS. Genes associated with longer RFS included PD-1 (p=0.003), ICOS (p=0.006), BTLA (p=0.033), and CTLA4 (p=0.02). In a composite immune score, CD4+ T cells had the strongest positive predictive value, while CD14+ monocytes and M2 macrophages had the strongest negative predictive values. CONCLUSIONS: Immune cell infiltration predicts clinical outcome in DDLPS, with CD4+ cells associated with better outcomes; CD14+ cells and M2 macrophages are associated with worse outcomes. Future checkpoint inhibitor studies in DDLPS should incorporate immunosequencing and gene expression profiling techniques that can generate immune landscape profiles.
Asunto(s)
Linfocitos T CD4-Positivos/metabolismo , Macrófagos/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Diferenciación Celular , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Liposarcoma , Masculino , Persona de Mediana Edad , Evaluación del Resultado de la Atención al Paciente , Estudios Retrospectivos , Adulto JovenRESUMEN
While half of the metastatic clear cell renal cell carcinomas (ccRCCs) involve the lungs, metastatic lesions have been described in various other organs, including glandular tissues such as the pancreas. Recent evidence suggests that ccRCC lesions affecting the pancreas are poorly responsive to immune checkpoint inhibition (ICI) but show superior responses to tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) signalling pathway. However, this has yet to be explored in ccRCC spreading to other glandular tissues. Here we present two cases of ccRCC with glandular metastases, the first to the pancreas and the second to the parotid gland. In both patients, ICI-based immunotherapy offered minimal clinical benefit, but both had durable responses to angiogenesis inhibitors. Given the anatomic similarity between the pancreas and parotid glands, ccRCC with involvement of the parotid gland may also benefit from VEGF-targeting TKIs as opposed to ICIs.
Asunto(s)
Carcinoma de Células Renales , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Neoplasias Renales , Neoplasias Pancreáticas/secundario , Neoplasias de la Parótida/secundario , Inhibidores de la Angiogénesis/uso terapéutico , Carcinoma de Células Renales/tratamiento farmacológico , Carcinoma de Células Renales/patología , Humanos , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/patología , Factor A de Crecimiento Endotelial VascularRESUMEN
Myxofibrosarcoma (MFS) is a well-recognized histotype of soft tissue sarcomas that generally presents with localized disease. Herein, we describe the case of a patient with metastatic MFS who experienced durable response to sixth-line therapy with temozolomide. Upon further progression, his tumor was notable for a high tumor mutational burden, and he was subsequently treated with seventh-line immunotherapy, atezolizumab, achieving a second durable response. This case highlights the role of immunotherapy after administration of alkylating agents. Review of the literature indicates that recurrent tumors treated with alkylating agents often experience hypermutation as a means of developing resistance and that checkpoint inhibitors are subsequently effective in these tumors. KEY POINTS: To the authors' knowledge, this is the first report of a patient with myxofibrosarcoma with high tumor mutational burden after administration of temozolomide monotherapy. Hypermutation may be a resistance mechanism for patients with soft tissue sarcoma who develop resistance to alkylating agents. Checkpoint inhibition may be effective therapy in patients with soft tissue sarcoma with high tumor mutational burden as a consequence of alternate systemic therapy resistance.
Asunto(s)
Fibrosarcoma , Recurrencia Local de Neoplasia , Adulto , Anticuerpos Monoclonales Humanizados , Fibrosarcoma/tratamiento farmacológico , Humanos , Masculino , Temozolomida/uso terapéuticoRESUMEN
Azelaic acid is a complex molecule with many diverse activities. The latter include anti-infective and anti-inflammatory action. The agent also inhibits follicular keratinization and epidermal melanogenesis. Due to the wide variety of biological activities, azelaic acid has been utilized as a management tool in a broad spectrum of disease states and cutaneous disorders. This paper reviews the clinical utility of azelaic acid, noting the quality of the evidence supporting each potential use.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Ácidos Dicarboxílicos/uso terapéutico , Dermatosis Facial/tratamiento farmacológico , Peca Melanótica de Hutchinson/tratamiento farmacológico , Enfermedades de la Piel/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Acné Vulgar/tratamiento farmacológico , Alopecia Areata/tratamiento farmacológico , Dermatitis Perioral/tratamiento farmacológico , Fármacos Dermatológicos/farmacología , Ácidos Dicarboxílicos/farmacología , Humanos , Melanosis/tratamiento farmacológico , Psoriasis/tratamiento farmacológico , Rosácea/tratamiento farmacológicoRESUMEN
Macrophages have key roles in tumor development and invasion in several human cancers, but little is known about their pathogenic role in cutaneous T-cell lymphoma (CTCL). Herein, we used PCR arrays to profile the expression of inflammatory cytokines in 12 patients with mycosis fungoides (MF), the most common variant of CTCL. Compared with normal controls, MF skin displayed increased mRNA levels of macrophage-related cytokines. Moreover, we detected CD163, a reliable marker of tumor-associated macrophages, in the tumor microenvironment of MF biopsies. To demonstrate that macrophages had a role in CTCL tumorigenesis, we xenografted human CTCL tumor cells in immunocompromised mice and compared tumor development using clodronate-containing liposomes to deplete macrophages in mice. Mice treated with clodronate-containing liposomes show markedly less tumor growth compared with mice treated with phosphate-buffered saline-containing liposomes (P<0.001). We also noted a strong correlation between macrophage depletion and decreased expression of vascular marker, CD31, and lymphatic marker, podoplanin, suggesting a role for macrophages in angiogenesis. In vitro, clodronate-containing liposomes killed activated murine M2 macrophages, but not Hut78 cells, demonstrating selective ability to induce apoptosis in macrophages. Our data indicate that macrophages have a critical role in the progression of Hut78 cell tumor formation in skin, thus providing a new therapeutic strategy for CTCL.
Asunto(s)
Linfoma Cutáneo de Células T/sangre , Macrófagos/citología , Neoplasias Cutáneas/sangre , Animales , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Células de la Médula Ósea/citología , Línea Celular Tumoral , Ácido Clodrónico/química , Citocinas/metabolismo , Modelos Animales de Enfermedad , Humanos , Inflamación/metabolismo , Liposomas/química , Linfoma Cutáneo de Células T/patología , Macrófagos/metabolismo , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones SCID , Micosis Fungoide/metabolismo , Trasplante de Neoplasias , Fenotipo , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/metabolismo , Receptores de Superficie Celular/metabolismo , Neoplasias Cutáneas/patologíaRESUMEN
Although some research in the past has examined how physical limitations in strength or flexibility affect a golfer's performance, the performance outcome most measured was driving distance. Currently, there are no data that have examined the relationship between selected strength and flexibility variables and golf swing faults. The purpose of this study was to examine the relationship between Titleist Performance Institute (TPI) level 1 movement screen variables and 14 common golf swing faults. Thirty-six male and female golfers (mean age, 25.4 ± 9.9 years; height, 175.9 ± 16.2 cm; mass, 76.2 ± 14.6 kg; handicap, 14.2 ± 10.4) participated. Twelve physical tests of strength, flexibility, and balance were assessed using the TPI level 1 golf fitness screening tool. Golfers then hit 4 golf shots (with a 5-iron) while being videoed, and those were then analyzed for 14 different golf swing faults (using V1Pro software). Three significant associations between a physical limitation and a particular golf swing fault were found: toe touch and early hip extension (p = 0.015), bridge on right side with both early hip extension (p = 0.050), and loss of posture (p = 0.028). In addition, an odds ratio showed that when a golfer could not overhead deep squat or single leg balance on left side, they were 2-3 times more likely to exhibit a early hip extension, loss of posture, or slide during the golf swing, as compared with those who could perform a correct overhead deep squat. Based on our findings, it is important for the golf fitness professional to particularly address a golfer's core strength, balance, and hamstring flexibility to help avoid common golf swing faults, which affect a golfer's ball striking ability and ultimately their performance.